GKGülhan Özçelik Köker

Gülhan Özçelik Köker

*This is an algorithmically generated author record based on publicly available information.

Gülhan Özçelik Köker has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinicopathological characteristics, immunohistochemistry-based surrogate subtypes and survival in male breast cancer

    by Mehmet Fatih Özbay, Mehmet Hünür, Sertaç Vurğun, Ayşe Tan Doğruel, Gülhan Özçelik Köker, Sema Sezgin Göksu, Mustafa Karaca

    Aims: Male breast cancer (MBC) is a rare disease, and treatment approaches are largely extrapolated from female breast cancer. This study aims to evaluate clinicopathological features, immunohistochemistry-based surrogate subtypes, treatment approaches, and survival outcomes in MBC patients from Turkiye, where data on this rare disease remain limited. Methods: Forty-seven MBC patients diagnosed between 2005-2024 were retrospectively analyzed. Demographic characteristics, tumor features, immunohistochemistry-based surrogate subtypes, treatment modalities, and survival data were evaluated. Survival analyses were performed using the Kaplan-Meier method, and group comparisons were conducted using the log-rank test. Exploratory associations with overall survival (OS) were evaluated using univariate Cox regression analysis. Analyses used available cases without imputation. Surrogate subtypes were derived from ER, PR, HER2 and Ki-67; HR-positive/HER2negative tumours without Ki-67 were not assigned to luminal A-like or luminal B-like/HER2-negative categories. Results: The median age was 58.4 years (range 31–90), and the median follow-up was 54.9 months (range 2.8–197.3). Stage II was the most common presentation (59.5%), and stage III–IV disease was present in 28.6%. ER/PR/HER2 data were available for 44 patients. Complete five-category immunohistochemistry-based surrogate subtype classification was possible in 35 patients: luminal A-like 31.4% (11/35), luminal B-like/HER2-negative 42.9% (15/35), luminal B-like/HER2-positive 17.1% (6/35), HER2 positive/non-luminal 5.7% (2/35), and triple-negative 2.9% (1/35). Nine additional HR-positive/HER2-negative tumours could not be divided into the two HER2-negative luminal categories because Ki-67 was unavailable. ER positivity was 93.2%, PR positivity 86.4%, and HER2 positivity 18.2%. OS was evaluable in 46 patients; the median OS was 194.3 months and the median disease-free survival was 155.8 months. In exploratory univariate Cox analysis, older age (per 10-year increase: HR 1.76, 95% CI 1.03–2.98, p=0.037), grade 3 histology (HR 3.35, 95% CI 1.17–9.59, p=0.024) and a high Ki-67 index (≥20% vs

  • Open Access

    Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance

    by Kübra Şahin, Yasin Şahintürk, Gökhan Köker, Gülhan Özçelik Köker, Feyzi Bostan, Mehmet Kök, Seyit Uyar, Ayhan Hilmi Çekin

    Background: To evaluate the impact of concomitant use of probiotic BB-12 in metformin-treated patients with type 2 diabetes or prediabetes on glycemic control, metformin-related gastrointestinal side effects, and treatment compliance. Methods: A total of 156 patients (mean [standard deviation] age: 50.9 [9.9 years], 74.4% females) with newly diagnosed type 2 diabetes or prediabetes were randomly assigned to receive either metformin alone (n = 84, MET group) or metformin plus Bifidobacterium animalis subsp. lactis (BB-12) probiotic (n = 72, MET-PRO group). Data on body mass index (kg/m2), fasting blood glucose (mg/dL), blood lipids, and glycated hemoglobin (HbA1c) levels were recorded at baseline and at the third month of therapy. Data on gastrointestinal intolerance symptoms and treatment noncompliance were also recorded during post-treatment week 1 to week 4. Results: MET-PRO versus MET therapy was associated with a significantly higher rate of treatment compliance (91.7% vs 71.4%, P = .001), greater reduction from baseline HbA1c values (0.9 [0.4-1.6] vs 0.4 [0-1.6] %, P < .001) and lower likelihood of gastrointestinal intolerance symptoms, including abdominal pain (P = .031 to <.001), diarrhea (P = .005 to <.001) and bloating (P = .010 to <.001). Noncompliance developed later (at least 15 days after the therapy) in a significantly higher percentage of patients in the MET group (P = .001 for 15–21 days and P = .002 for 22–28 days). Conclusion: In conclusion, the present study proposes the benefit of combining probiotics with metformin in the treatment of patients with T2D or prediabetes in terms of improved glycemic control and treatment adherence rather than correction of dyslipidemia or weight reduction. Cite this article as: Şahin K, Şahintürk Y, Köker G, et al. Metformin with versus without concomitant probiotic therapy in newly diagnosed patients with type 2 diabetes or prediabetes: A comparative analysis in relation to glycemic control, gastrointestinal side effects, and treatment compliance. Turk J Gastroenterol. 2022;33(11):925-933.


  • Geriatrik popülasyonda kolestatik karaciğer hastalıklarında etiyoloji ve tanısal yaklaşım: 185 vakalık tek merkez deneyimi

    by Gökhan Köker, Seyit Uyar, Gülhan Özçeli̇k, Mehmet Çatli, Yasin Şahi̇ntürk, Feyzi Bostan, Ayhan Çeki̇n

    Giriş ve Amaç: Kolestaz etiyolojik nedenlerinin ve klinik bulgularının 65 yaş üstü hastalarda geniş hasta popülasyonu ile dökümante edilmesi amaçlandı. Gereç ve Yöntem: Kolestaz nedeniyle yatışı yapılan 65 yaş ve üstü hastalar retrospektif olarak şikayetleri, laboratuvar parametreleri ve görüntüleme sonuçlarına göre değerlendirildi. Benign ve malign etiyolojik nedenler olarak iki gruba ayrılan hastalarda malignite göstergesi olabilecek parametreler için ileri analiz yapıldı. Bulgular: Çalışmamıza retrospektif olarak 65 yaş ve üstü 185 hasta dahil edildi. 109 (%58.9) hastanın etiyolojisi benign, 69 (%37.3) hastanın malign nedenlere bağlı olarak saptandı. 56 hastada (%30.3) koledokolitiazis, 25 hastada (%13.5) kolanjioselüler karsinom, 23 hastada (%12.4) pankreas kanseri en sık görülen tanılardı. En sık başvuru şikayeti karın ağrısıydı. Sarılık şikayetiyle başvuran hastaların %45.6’sı (n: 52) benign, %54.4’ü (n: 62) malign iken kilo kaybıyla başvuran hastaların %6.2’si benign, %93.8’i maligndi. Sarılık ve/veya kilo kaybı şikayetiyle başvuran hastaların malign olma ihtimali istatistiksel olarak anlamlı düzeyde yüksek saptandı (p < 0.001). Çok değişkenli analiz sonuçlarına göre total bilirübin ve alkalen fosfatazın diğer değişkenlerden bağımsız olarak malignite ile pozitif olarak ilişkili olduğu görüldü. Ultrasonografi ile 185 hastanın 85’ine (%46) tanı koyulabilirken, 100’üne (%54) ise tanı koyulamadığı görülmüştür. Sonuç: Geriatrik popülasyonda kolestaz etiyolojisinde benign sebepler daha sık görülmüştür. Sarılık ve kilo kaybı şikayetleri olan ve/veya bilirübin ve alkalen fosfataz düzeyi yüksek olan hastalarda ise malign hastalıklar ayırıcı tanıda öncelikli olmalıdır. Ultrasonografi geriatrik popülasyondaki kolestazlı hastalarda tanı koymada yetersiz bulunmuş, ileri görüntüleme tetkiklerine ihtiyaç duyulmuştur.